Lazcluze 240 mg – DIN 02555972
Lazcluze is Lazertinib Mesylate 240 mg (tablet), sold in Canada. It is used for lung neoplasms. It is supplied by Janssen Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Lazertinib Mesylate 240 mg
- Brand
- Lazcluze
- Strength
- 240 mg
- Used for
- Lung neoplasms
- Form
- Tablet
- Manufacturer
- Janssen Inc
- Drug class
- Cancer medicine (kinase inhibitor)
- Sold in
- Canada
- DIN
- 02555972
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Lazertinib used for?
Lazertinib is used for lung neoplasms.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
From the FDA-approved label on DailyMed (published May 07, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02555972.
- It names Lazcluze, Lazertinib Mesylate 240 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Lazcluze by Janssen Inc.
In Canada: prescription only.
Ingredients
Active: Lazertinib (Lazertinib Mesylate)